英文名稱 | Anti-Human EGFRxMET Bispecific Antibody(Amivantamab; JNJ-61186372) |
---|---|
中文名稱 | 埃萬(wàn)妥單抗 |
CAS號(hào) | 2171511-58-1 |
儲(chǔ)存條件 | -20°C for 3 years | In solvent: -80°C for 1 year |
規(guī)格 | 庫(kù)存 | 目錄價(jià) | 會(huì)員專享價(jià) | 數(shù)量 | |
---|---|---|---|---|---|
暫無(wú)牌價(jià)信息,您可以發(fā)送詢價(jià),我們會(huì)盡快給你回復(fù)。 |
英文名稱 | Anti-Human EGFRxMET Bispecific Antibody(Amivantamab; JNJ-61186372) |
---|---|
中文名稱 | 埃萬(wàn)妥單抗 |
CAS號(hào) | 2171511-58-1 |
儲(chǔ)存條件 | -20°C for 3 years | In solvent: -80°C for 1 year |
Amivantamab (JNJ-61186372) is a fully human EGFR-MET bispecific antibody that combats resistance in NSCLC through multifaceted mechanisms: ligand blockade, receptor degradation, and immune cell activation, including ADCC and trogocytosis. This innovative approach targets both primary and acquired resistance, offering a new therapeutic avenue for patients with EGFR and MET aberrations.
PMID: 34339292 PMCID: PMC8791812 DOI: 10.1200/JCO.21.00662
PMID: 32414908 DOI: 10.1158/2159-8290.CD-20-0116